In Vivo Evaluation of a Novel Long‐Term Intravascular Implantable Continuous Blood Glucose Monitor in an Ovine Model: A Glucotrack Inc. Investigation

Figures

• 

  Figure 1. Prototype Glucotrack CBGM device. The Glucotrack CBGM device consists of a device housing and one sensing lead. Minor updates were made to improve device longevity in following device prototypes used in the studies.

• 

  Figure 2. Pretermination imaging example. (A and B) Fluoroscopy images obtained prior to animal termination. Note that R‐IV and L‐IV are right intervascular implant and left intervascular implant, respectively.

• 

  Figure 3. Early example of accuracy of Glucotrack measurements during IVGTT at the 30‐ and 60‐day timepoints. (A and B) Glucotrack measurements (dark blue left; light blue right lines) and Accu‐Chek guide blood glucose measurements (orange circle) for Sheep #1 at the 30‐ and 60‐day timepoints. (C and D) Glucotrack measurements (dark blue left; light blue right lines) and Accu‐Chek Guide blood glucose measurements (orange circle) for Sheep #2 at the 30‐ and 60‐day timepoints.

• 

  Figure 4. Calibration example. (A and B) Glucotrack measurements (blue circles) and Accu‐Chek blood glucose measurements (orange circle) for 4 weeks before (A) and 4 weeks after (B) calibration at the 60‐day (scheduled on Day 57) IVGTT. Note that the current data spike observed at about Day 32 is due to an IVGTT.